New approaches to the prophylaxis and treatment of bacterial and fungal infections in allogeneic marrow transplant recipients.
Bacterial and fungal infections continue to be a major threat to bone marrow transplant recipients. While standardized approaches to empiric therapy with early inclusion of antibiotics active against Gram-positive organisms and against fungi may have improved the outcome of these patients during the past decade, other developments (e.g. increasing number of patients in older age groups, unrelated donors, mismatch transplants) may even have increased the problem. Current approaches to the prophylaxis and treatment of these infections are discussed. Concerning fungal infections especially the new azoles and new approaches of amphotericin B administration are of interest.
Schuler
U
U
Department of Internal Medicine I, Technical University of Dresden, Germany.
Ehninger
G
G
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control* / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000517:prevention & control; D003666:Decontamination; D004352:Drug Resistance, Microbial; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D017053:Infection Control / Q000191:economics / Q000379:methods*; D015337:Multicenter Studies as Topic; D009181:Mycoses / Q000517:prevention & control* / Q000628:therapy; D010356:Patient Isolation; D011292:Premedication; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies
D000890:Anti-Infective Agents; D016298:Hematopoietic Cell Growth Factors; D016756:Immunoglobulins, Intravenous